Ascentage Pharma details October 2025 investor events

Ascentage Pharma Group International filed a Form 6-K noting that it issued a press release on October 7, 2025.

Accepted by SEC EDGAR 10/07/2025 - 09:15 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Ascentage Pharma Group International filed a Form 6-K noting that it issued a press release on October 7, 2025. The press release, furnished as Exhibit 99.1, announces that the company will participate in three investor conferences in October 2025. These conferences are opportunities for the company to present its business and engage with the investment community, but no financial results, transactions, or other material changes are detailed in this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ascentage Pharma Group International (AAPG) disclose in this Form 6-K?

The Form 6-K states that Ascentage Pharma Group International issued a press release on October 7, 2025, about its participation in three investor conferences in October 2025, and furnishes that release as Exhibit 99.1.

Does this Ascentage Pharma (AAPG) Form 6-K include financial results or earnings data?

No. The Form 6-K only references a press release about upcoming investor conferences in October 2025 and does not present financial results or earnings data.

What is included as Exhibit 99.1 to Ascentage Pharma’s (AAPG) Form 6-K?

Exhibit 99.1 is described as a press release dated October 7, 2025, titled “Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025.”

Who signed this Ascentage Pharma Group International (AAPG) Form 6-K?

The Form 6-K is signed on behalf of Ascentage Pharma Group International by Dajun Yang, who is identified as the Chief Executive Officer.

What is the main purpose of this Ascentage Pharma (AAPG) Form 6-K for October 2025?

The main purpose is to formally furnish the company’s press release announcing participation in three investor conferences in October 2025 to the U.S. securities markets.

Where is Ascentage Pharma Group International’s principal executive office located?

The filing lists the principal executive office address as 68 Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu, China.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of October 2025

Commission File Number: 001-42484

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒            Form 40-F ☐

On October 7, 2025, Ascentage Pharma Group International issued a press release entitled, “Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025”. A copy of the press release is furnished as Exhibit 99.1 to this Report.

1

INDEX TO EXHIBITS

Exhibit Number		Exhibit Title
99.1		Press Release dated October 7, 2025

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ASCENTAGE PHARMA GROUP INTERNATIONAL
Date: October 7, 2025	/s/ Dajun Yang
	Name: Dajun Yang
	Title: Chief Executive Officer

3